Subsequently, we applied the mathematical modeling method RACIPE17 to each GRN to evaluate how well the GRN steady states capture the TF activity profiles from both the normal controls and the AML patients and how flexibly the GRN drives transitions between normal and disease states, from which we identified an optimal GRN. This evidence concerns the gene TF and acute myeloid leukemia.